SCHEMBL16331804

SCHEMBL16331804

COc1ccc(Nc2nccc3c2cc(-c2ccsc2)n3C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.50
▸ RAB9A P51151 5/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ LMNA P02545 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ FYN P06241 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ MAPT P10636 2/20 0.40
▸ GRM1 Q13255 1/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40
▸ GABRA5 P31644 1/20 0.40
▸ GABRA3 P34903 1/20 0.40
▸ GABRA2 P47869 1/20 0.40
▸ HTT P42858 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16332015 0.88 FYN (0.48) LMNATP53FYNMEN1KMT2A
SCHEMBL16332052 0.87 FYN (0.39) NPC1RAB9ASMN1; SMN2LMNATP53
SCHEMBL16332075 0.87 FYN (0.40) NPC1RAB9ASMN1; SMN2LMNATP53
SCHEMBL16331528 0.87 CYP2A6 (0.44) NPC1RAB9ASMN1; SMN2LMNATP53
SCHEMBL16331729 0.86 MEN1 (0.47) NPC1SMN1; SMN2LMNAFYNMEN1
SCHEMBL16331822 0.85 FYN (0.47) NPC1RAB9ASMN1; SMN2LMNATP53
SCHEMBL16373494 0.85 FYN (0.37) NPC1RAB9ASMN1; SMN2LMNATP53
SCHEMBL16331293 0.84 ABCG2 (0.37) FYNKDM4ECYP2C9CYP2C19LCK
SCHEMBL16331999 0.83 CTSC (0.44) NPC1RAB9ASMN1; SMN2FYNMEN1
SCHEMBL16331728 0.83 TGFBR1 (0.45) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458463-B2 Method for treatment of diabetes by a small molecule inhibitor for GRK5 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2016-10-04 — — US claimed
EP-2818472-A1 Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2014-12-31 — — EP claimed
EP-2818472-A1 Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2014-12-31 — — EP disclosed
Send feedback